Ibyra 150 pack, olaparib by Zydus
Prescription cancer medicine

Olaparib

Brand reference: Lynparza, Bracanat, Ibyra, OBparp, Lynza

BRCA-mutated ovarian, breast, pancreatic and prostate cancers (PARP inhibitor).

FormTabletStrengths shown100 mg, 150 mgPrescriptionRequired
Add to enquiry list

Add this medicine to a consolidated enquiry. This does not reserve stock, create an order or confirm availability.

What is Olaparib used for?

BRCA-mutated ovarian, breast, pancreatic and prostate cancers (maintenance or treatment)

Precision-oncology PARP inhibitor.

In simple terms

Olaparib is a PARP inhibitor. In cancers with faulty DNA repair (such as BRCA mutations), it blocks the backup repair pathway too, so the cancer cells accumulate fatal DNA damage.

Brand and medicine details

Active ingredient
Olaparib
Dispensing location
Confirmed only if an enquiry can proceed.
Brand references
Lynparza, Bracanat, Ibyra, OBparp, Lynza
Strengths shown
100 mg, 150 mg
Dosage form
Tablet

A catalogue brand reference does not confirm the manufacturer, pack, source or availability for an individual enquiry. Confirm any proposed substitution with the treating oncology team.

How it may be prescribed

Usually taken twice daily, with or without food, continuously as the oncologist prescribes. Requires confirmation of a relevant mutation.

Possible side effects to discuss with the care team

  • Nausea and fatigue
  • Anaemia and low blood counts (monitored)
  • Loss of appetite
Important safety information

For patients with a confirmed BRCA/HRD mutation, under specialist supervision with blood monitoring. Supplied only against a valid specialist prescription.

Common questions about Olaparib

Is generic Olaparib genuine medicine?

Yes. Medrack refers only licensed medicine from a controlled supply chain, either the originator brand or a licensed branded generic from an established manufacturer. It is not an unbranded or unverified copy. The exact brand, manufacturer and pack are confirmed at the enquiry stage, and any proposed medicine should be reviewed with the treating oncology team.

Do I need a genetic test for olaparib?

Yes. Olaparib is prescribed where a relevant mutation, such as BRCA, is confirmed. The prescription and the recorded indication are checked as part of the enquiry review, before any next step is discussed.

Do I need a prescription for Olaparib?

Yes. Olaparib is a prescription medicine. You can start an enquiry before you have the prescription in hand, but nothing proceeds until a current prescription issued in the patient's name has been received and checked. You upload it privately as part of the enquiry.

What happens after you enquire

Every enquiry is assessed individually. A listing on this page does not confirm availability, a dispensing pharmacy or a delivery.

  1. You send an enquiry

    Add the prescribed medicine and upload the current prescription. This records a request for assessment, not an order.

  2. We check the prescription

    The medicine, prescription, patient details, destination and supporting documentation are reviewed case by case.

  3. We prepare a referral and written terms

    Any proposal identifies the responsible dispensing party, the dispensing country, the total charges and the cancellation terms.

  4. You confirm and pay

    Nothing proceeds until you accept the disclosed terms. Payment is requested only after that written summary has been provided.

  5. Dispatch and delivery

    Dispatch and delivery dates are estimates. Timing can change with availability, documentation, customs or regulatory decisions outside our control.

Full detail is in delivery and fulfilment, order and fulfilment terms and cancellation and refunds.

Before you send an enquiry

These guides explain what to check and what to ask, so the enquiry arrives complete.

Build an enquiry list

Add Olaparib

Choose the prescribed strength and quantity. You can add more medicines before sending one enquiry.

Adding a medicine does not reserve stock or create an order.

This listing does not support starting, stopping, switching or changing treatment. Keep the treating oncology team involved in all clinical decisions and monitoring.